1700 related articles for article (PubMed ID: 28461123)
1. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
Hozumi H; Enomoto N; Kono M; Fujisawa T; Inui N; Nakamura Y; Sumikawa H; Johkoh T; Nakashima R; Imura Y; Mimori T; Suda T
PLoS One; 2015; 10(3):e0120313. PubMed ID: 25789468
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
Zhan X; Yan W; Wang Y; Li Q; Shi X; Gao Y; Ye Q
BMC Pulm Med; 2021 Feb; 21(1):57. PubMed ID: 33579248
[TBL] [Abstract][Full Text] [Related]
7. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
8. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
[No Abstract] [Full Text] [Related]
9. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
Kaieda S; Gono T; Masui K; Nishina N; Sato S; Kuwana M;
PLoS One; 2020; 15(6):e0234523. PubMed ID: 32525903
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
[TBL] [Abstract][Full Text] [Related]
11. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.
Yoshifuji H; Fujii T; Kobayashi S; Imura Y; Fujita Y; Kawabata D; Usui T; Tanaka M; Nagai S; Umehara H; Mimori T
Autoimmunity; 2006 May; 39(3):233-41. PubMed ID: 16769657
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis.
Matsushita T; Hasegawa M; Fujimoto M; Hamaguchi Y; Komura K; Hirano T; Horikawa M; Kondo M; Orito H; Kaji K; Saito Y; Matsushita Y; Kawara S; Yasui M; Seishima M; Ozaki S; Kuwana M; Ogawa F; Sato S; Takehara K
J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study.
Nakazawa M; Kaneko Y; Takeuchi T
Clin Rheumatol; 2018 Mar; 37(3):765-771. PubMed ID: 28975463
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM.
Takato H; Waseda Y; Watanabe S; Inuzuka K; Katayama N; Ichikawa Y; Yasui M; Fujimura M
Respir Med; 2013 Jan; 107(1):128-33. PubMed ID: 23137883
[TBL] [Abstract][Full Text] [Related]
16. Survival and outcomes after lung transplantation for connective tissue disease-associated interstitial lung diseases.
Yang X; Wei D; Liu M; Wu B; Zhang J; Xu H; Ye S; Liu F; Hu C; Chen J
Clin Rheumatol; 2021 Sep; 40(9):3789-3795. PubMed ID: 33755837
[TBL] [Abstract][Full Text] [Related]
17. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
18. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.
Lega JC; Fabien N; Reynaud Q; Durieu I; Durupt S; Dutertre M; Cordier JF; Cottin V
Autoimmun Rev; 2014 Sep; 13(9):883-91. PubMed ID: 24704867
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
20. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.
Hamaguchi Y; Fujimoto M; Matsushita T; Kaji K; Komura K; Hasegawa M; Kodera M; Muroi E; Fujikawa K; Seishima M; Yamada H; Yamada R; Sato S; Takehara K; Kuwana M
PLoS One; 2013; 8(4):e60442. PubMed ID: 23573256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
